The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase 2 trial comparing amrubicin (A) with re-challenge of platinum doublet (P) in patients (pts) with sensitive-relapsed small-cell lung cancer (SCLC).
Atsushi Nakamura
No relevant relationships to disclose
Akira Inoue
No relevant relationships to disclose
Makoto Maemondo
No relevant relationships to disclose
Yoshiaki Mori
No relevant relationships to disclose
Satoshi Oizumi
No relevant relationships to disclose
Masao Harada
No relevant relationships to disclose
Shingo Takanashi
No relevant relationships to disclose
Naoto Morikawa
No relevant relationships to disclose
Takashi Ishida
No relevant relationships to disclose
Ichiro Kinoshita
No relevant relationships to disclose
Hiroshi Watanabe
No relevant relationships to disclose
Toshiro Suzuki
No relevant relationships to disclose
Taku Nakagawa
No relevant relationships to disclose
Ryota Saito
No relevant relationships to disclose
Toshihiro Nukiwa
No relevant relationships to disclose